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Abstract
Background: Several biomarkers and prognostic scores have been evaluated to predict prognosis in community-
acquired pneumonia (CAP). Optimal risk stratification remains to be evaluated. The aim of this study was to
evaluate serum cortisol as biomarker for the prediction of adverse outcomes independently of the CRB-65 score
und inflammatory biomarkers in a large cohort of hospitalised patients with CAP.
Methods: 984 hospitalised CAP-patients were included. Serum cortisol was measured and its prognostic accuracy
compared to the CRB-65 score, leucocyte count and C-reactive protein. Predefined endpoints were 30-day
mortality and the combined endpoint critical pneumonia, defined as presence of death occurring during antibiotic
treatment, mechanical ventilation, catecholamine treatment or ICU admission.
Results: 64 patients died (6.5%) and 85 developed critical pneumonia (8.6%). Cortisol levels were significantly
elevated in both adverse outcomes (p < 0.001) and predicted mortality (AUC 0.70, cut-off 795 nmol/L) and critical
pneumonia (AUC 0.71) independently of all other measured variables after logistic regression analysis (p = 0.005
and 0.001, respectively). Prognostic accuracy of CRB-65 was significantly improved by adding cortisol levels
(combined AUC 0.81 for both endpoints). In Kaplan-Meier analysis, cortisol predicted survival within different CRB-
65 strata (p = 0.003). In subgroup analyses, cortisol independently predicted critical pneumonia when compared to
procalcitonin, the CURB65 score and minor criteria for severe pneumonia according to the 2007 ATS/IDSA-
guideline.
Conclusion: Cortisol predicts mortality and critical disease in hospitalised CAP-patients independently of clinical
scores and inflammatory biomarkers. It should be incorporated into trials assessing optimal combinations of clinical
criteria and biomarkers to improve initial high risk prediction in CAP.
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Background
A disease severity based approach with initial risk strati-
fication is required to guide management and treatment
decisions in CAP. International guidelines recommend
prognostic scores to support clinical decision on man-
agement as outpatient, inpatient or admission to ICU.
The most established score systems are the PSI-score
and the CURB or CRB-65 scores, which perform com-
parably for mortality prediction and identification of low
risk patients suitable for an outpatient management
strategy [1-3]. Amongst them, the CRB-65 score is the
most easily to calculate and widely used in Europe [4,5].
Additionally, biomarkers have been found to improve
risk stratification and management decisions in CAP.
Procalcitonin (PCT) has been demonstrated to provide
additional information by identifying low risk patients
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any medium, provided the original work is properly cited.[6], as parameter to judge treatment response when
sequentially measured during treatment [7] and as a
tool to guide antibiotic treatment duration [8]. Other
biomarkers like pro-ADM, pro-ANP, pro-BNP, pro-
vasopressin and d-dimer have been associated with mor-
tality in CAP [9-13].
However, accurate mortality prediction does not auto-
matically lead to accurate identification of patients devel-
oping critical disease in need for intensive care treatment
[14]. Both the CRB-65 and PSI scores lack accuracy for
the prediction of high risk situations resulting in ICU
admission [14]. Other scoring systems have been pro-
posed to identify patients requiring admission to ICU like
the modified American Thoracic Society (ATS)-rule [15]
and more recently the new ATS/Infectious Diseases
Society of America (IDSA)-recommended score [16].
However, both scores still fail to identify a significant
proportion of patients with early deterioration and have
poor positive predictive values for ICU-admission
[17-19]. Thus, identifying patients with a high benefit
from initial intensive management strategies in CAP
remains an important task to be done [20].
Recently, serum cortisol concentration was shown to
be associated with severity and mortality in CAP in three
small trials [21-23]. Additionally, we demonstrated that
cortisol predicts persistent clinical instability, making it a
potential parameter to improve the identification of
patients with high risk for a complicated disease course
[21].
The aim of this trial was, to evaluate serum cortisol as
biomarker for the development of severe disease requiring
more intensive monitoring and management strategies as
well as 30-day mortality in a large cohort of hospitalised
CAP-patients. Additionally, we studied the independent
contribution of serum cortisol to the prognostic properties
of the CRB-65 score and inflammatory biomarkers.
Methods
Patients
Hospitalised CAP patients were recruited from a multicen-
tre national CAP-study in Germany, the German Compe-
tence network for the study of CAP (CAPNETZ). Detailed
description of the CAPNETZ methodology is given else-
where [24]. Inclusion criteria for entering the study are: age
≥ 18 years, pulmonary infiltrate diagnosed by chest x-ray,
clinical symptoms consisting of cough or purulent sputum
or positive auscultation or fever. Among the exclusion cri-
teria is systemic steroid medication of ≥ 20 mg predniso-
lone equivalent per day for more than 14 days. Patients for
this study were recruited in 12 clinical CAPNETZ centers
between 10/2002 and 12/2008. All clinical parameters are
stored in an electronic database. Written informed consent
was obtained from every patient prior to inclusion in the
study. The study was approved by the ethical review board
of the University of Magdeburg, Germany (#104/01).
Comorbidities in the present study were defined as
presence of one or more of the following: congestive
heart failure, COPD, chronic renal disease, chronic liver
disease, cerebrovascular disease, malignancy, or diabetes
mellitus.
The CRB-65 score was determined in all patients as
described previously [25].
All patients were followed up according to a standar-
dized data sheet for at least 180 days.
Laboratory values
Venous blood samples were collected within 24 h after
f i r s tp r e s e n t a t i o na n di n c l u s i o ni nt h eC A P N E T Zs t u d y
and stored centrally at -70°C. Leucocyte (WBC) count and
urea were determined by the local hospital laboratories.
Serum C-reactive protein (CRP) was centrally measured
by nephelometry with a commercially available assay
(Behring Diagnostics, Marburg, Germany). Serum PCT
was centrally determined by an immunofluorescent assay
(sensitive KRYPTOR, B.R.A.H.M.S AG, Henningsdorf,
Germany). Serum cortisol was centrally analysed by a
commercially available chemiluminescence immunoassay
(Roche Diagnostics, Mannheim, Germany). This assay has
a measurement range of 0.5-1750 nmol/L, higher concen-
trations were analysed by dilution of the serum sample
according to the manufacturers protocol.
Outcome parameter
Predefined outcome variables were survival within
30 days after first contact and the combined endpoint cri-
tical pneumonia, defined as the presence of one of the
following: death occurring during antibiotic treatment,
mechanical ventilation, catecholamine treatment or ICU
admission.
Statistics
Two group comparisons were calculated by the Mann-
Whitney U-test. Univariate and multivariate analyses were
performed to predict the binary endpoints by including
the CRB-65-score, the measured laboratory parameters
WBC, CRP, cortisol, and all documented comorbid condi-
tions and demographic factors given in Table 1. For multi-
variate analyses a logistic regression model with stepwise
forward variable selection was employed.
Receiver operating characteristic (ROC) curve analysis
was used to determine the diagnostic properties of pre-
dictive parameters, optimal cut-off values were deter-
mined by Youden’si n d e x .T oc o m p a r et h ep r e d i c t i v e
value of cortisol and the CRB-65 score, a binary logistic
regression model of both parameters was used and the
predicted probability derived from that model was
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calculated by using the Mantel-Haenszel estimate.
To assess the influence of cortisol concentrations on
mortality, we produced Kaplan-Meier survival curves
according to cortisol quartiles or cut-off value and strati-
fied by CRB-65 score. Comparison between the groups
was performed by log-rank test. A p-value of ≤ 0.05 (two-
sided) was considered statistically significant. Statistical
analyses were performed with SPSS for Windows, version
17.0 (SPSS Inc., Chicago, IL, USA).
Results
984 patients were included in the study, their baseline
characteristics are summarised in Table 1.
A causative microbiological pathogen was detected in
195 patients (20%). Of these, typical bacteria were found
in 84 patients (43%), atypical bacteria in 64 (33%), viruses
in 29 (15%) and mixed infection in 18 (9%). Streptococcus
pneumoniae was the most frequently isolated pathogen
(n = 71, 36%)
There were 64 (6.5%) non-survivors at day 30 after the
first contact; their characteristics are shown in Table 1.
Mortality rates within the different CRB-65 score groups
were 0.7% (0 points), 7.7% (1 point), 18.2% (2 points),
21.1% (3 points) and 100% (4 points). The predefined cri-
teria for the combined endpoint of critical pneumonia
occurred in 85 patients (8.6%): Death during antimicrobial
treatment (N = 37), ICU-admission (N = 19, 2 died during
antimicrobial treatment), mechanical ventilation (N = 44,
11 of them on ICU, 2 more died during antimicrobial
treatment) or catecholamine treatment (N = 5, all on
ICU).
Serum cortisol levels on admission were significantly
higher in non-survivors when compared to survivors
(median 870 [IQR 624-1359] vs. 602 [407-843] nmol/l,
p < 0.001) and in patients with critical pneumonia ver-
sus noncritical pneumonia (median 972 [626-1520] vs.
598 [406-837] nmol/l, p < 0.001, Table 1), and increased
with increasing CRB-65 score (Figure 1). Cortisol values
for the different criteria of critical pneumonia are shown
in Table 2.
In multivariate analysis including all variables given in
Table 1, only cortisol level (p = 0.005 and 0.001 per
IQR-increase, respectively), CRB-65 score, pre-existing
congestive heart failure and male sex independently pre-
dicted both endpoints (Table 3).
This was confirmed by ROC-curve-analysis, showing
that serum cortisol was associated with both predefined
Table 1 Baseline characteristics of patients
characteristic Total
(n = 984)
Non-survivors
a
(N = 64)
Survivors
a
(N = 920)
p-value
b Critical CAP
c
(N = 85)
No critical CAP
c
(N = 899)
p-value
b
Age (years ± SD) 58.7 (± 18.1) 75.4 (± 9.8) 57,5 (± 17.9) < 0.001 69.5 (± 13.4) 57.7 (± 18.1) < 0.001
Male sex N (%) 558 (56.7) 46 (71.8) 512 (55.7) 0.011 59 (69) 499 (56) 0.013
Smoker N (%) 309 (31.4) 15 (23.4) 294 (32.0) 0.15 28 (32.9) 281 (31.3) 0.75
Prior antibiotics N (%) 276 (28.0) 12 (18.8) 264 (28.7) 0.09 15 (17.6) 261 (29.0) 0.026
Nursing home N (%) 28 (2.8) 7 (10.9) 21 (2.3) < 0.001 10 (11.8) 18 (2.0) < 0.001
Pathogen established N(%) 195 (19,8) 13 (20,3) 182 (19,8) 0.92 23 (27,1) 172 (19,1) 0.08
Comorbidities N (%)
Congestive heart failure 150 (15.2) 29 (45.3) 121 (13.2) < 0.001 31 (36.5) 119 (13.3) < 0.001
Chronic respiratory disease 360 (36.6) 27 (42.9) 333 (36.4) 0.30 41 (48.8) 319 (35.6) 0.017
Chronic renal disease 71 (7.2) 17 (27.0) 54 (5.9) < 0.001 14 (16.7) 57 (6.4) < 0.001
Chronic liver disease 33 (3.4) 2 (3.1) 31 (3.4) 0.91 0 (0) 33 (3.7) 0.07
Cerebrovascular disease 60 (6.1) 11 (17.2) 49 (5.3) < 0.001 11 (12.9) 49 (5.5) 0.006
Malignancy 88 (8.9) 16 (25.0) 72 (7.9) < 0.001 13 (15.3) 75 (8.4) 0.034
Diabetes mellitus 164 (16.7) 20 (31.3) 144 (15.7) 0.001 27 (31.8) 137 (15.2) < 0.001
CRB-65 N (%) < 0.001 < 0.001
0 417 (42.4) 3 (4.7) 414 (45.0) 9 (10.6) 408 (45.4)
1 415 (42.2) 32 (50) 383 (41.6) 31 (36.5) 384 (42.7)
2 132 (13.4) 24 (37.5) 108 (11.7) 34 (40.0) 98 (10.9)
3 19 (1.9) 4 (6.3) 15 (1.6) 10 (11.8) 9 (1)
4 1 (0.1) 1 (1.6) 0 (0) 1 (1.2) 0 (0)
Biomarker (median, IQR
d)
Cortisol (nmol/L) 621 (419-866) 870 (624-1359) 602 (407-843) < 0.001 972 (626-1520) 598 (406-837) < 0.001
WBC
e (10
9/mL) 10.7 (8.0-14.5) 13.2 (9.4-16.8) 10.6 (8.0-14.3) 0.003 13.6 (10.2-17.1) 10.5 (7.9-14.3) < 0.001
CRP
f (mg/L) 71.9 (18.8-167) 121.3 (55-230) 67.9 (18-163) < 0.001 141 (73-246) 66 (17-158) < 0.001
a survival at 30 days;
b bold values indicate significant differences;
c critical CAP = presence of one of the following: death occurring during antibiotic treatment,
mechanical ventilation, catecholamine treatment or ICU admission;
d IQR = interquartile range;
e WBC = leucocyte count;
f CRP = C-reactive protein
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0.71 for critical pneumonia). The optimal cut-off value
was calculated with 795 nmol/l with a sensitivity of 66%
and specificity of 71% (OR 4.7 [95%-CI: 2.8-8.1], p <
0.001) for 30-day mortality. Sensitivity and specificity for
critical pneumonia were 64% and 72% (OR 4.5 [95%-CI:
2.8-7.1], p < 0.001).
As shown in binary logistic regression analysis, the com-
bined use of CRB-65 and cortisol significantly improved
the prediction of 30-day mortality (AUC = 0.81, p = 0.001)
and critical pneumonia (AUC = 0.81, p = 0.002) when
compared to the CRB-65 score alone (AUC = 0.76 and
0.77, respectively, Figures 2 and 3). This result remained
significant, when CRP and WBC were added in the binary
regression analysis (p = 0.006 and p = 0.018 for cortisol).
WBC did not add significantly to the CRB-65 score for
both endpoints, CRP improved prediction of critical pneu-
monia (combined CRP + CRB-65 AUC = 0.81, p = 0.004),
but not 30-day mortality (p = 0.49).
Independent prediction of survival by cortisol could also
be demonstrated by Kaplan-Meyer survival analysis. Survi-
val was significantly different within cortisol-quartiles (p <
0.001, Figure 4), and this prediction persisted within the
CRB-65 classes (p = 0.002-0.003, Figures 5, 6, 7).
Urea was available from 889 patients (90%), and in this
subgroup a post-hoc analysis of the CURB- and
CURB65-scores was performed. The CURB-score pre-
dicted 30-day mortality and critical pneumonia equally to
the CRB-65 score with an AUC of 0.77 and 0.78, respec-
tively. The corresponding values for the CURB-65 score
were 0.81 and 0.79, which was a superior to the CRB65
score (p = 0.001). If cortisol was added, further significant
improvement of prediction resulted for both scores and
endpoints (cortisol + CURB: AUC 0.81 and 0.82; p =
0.009 and < 0.001; cortisol + CURB65: AUC 0.84 and
0.82; p = 0.02 and < 0.001, respectively).
PCT was not routinely measured in this trial. However,
in 643 patients (65.3%) initial PCT levels were available
and post-hoc analysis of these patients was performed.
Median PCT-concentration was 0.11 ng/ml (IQR 0.06-
0.33), with significantly higher values in non-survivors
(0.40 ng/ml [0.15-2.06]) vs. survivors (0.10 ng/ml [0.06-
0.30], p < 0.001). PCT predicted 30-day mortality (AUC =
0.73) and critical pneumonia (AUC = 0.74) by ROC-
curve-analysis. In that subgroup, both PCT and cortisol
tended to improve the predictive potential of CRB-65
score for 30-day-mortality, however in binary logistic
regression analysis including all three variables, the added
predictive value was not significant (p = 0.27 for PCT, p =
0.057 for cortisol). If critical pneumonia was used as
dependent variable, only cortisol added significantly and
independently of PCT to the prognostic accuracy of CRB-
65 (CRB-65 AUC = 0.77; CRB-65 + cortisol AUC = 0.82,
p < 0.001). The combined addition of both biomarkers to
CRB-65 showed no further improvement.
To assess the prognostic relevance of cortisol in com-
parison to the suggested minor criteria to identify
patients in need of ICU-admission by the ATS/IDSA
2007 guideline [16], we additionally performed a post-
hoc analysis on the 425 patients (43%) with all 8 minor
criteria (except multilobar infiltrates: no data) available.
By including these factors and serum cortisol into a logis-
tic multivariate regression analysis, significant indepen-
dent prediction of critical pneumonia was seen only for
cortisol (OR 1.78 per IQR-increase, p = 0.001) and the
three CRB-factors (confusion: OR 5.7, p < 0.001;
Figure 1 Boxplots of cortisol levels by severity of CAP
according to CRB-65 score. * 1 case (cortisol 4509 nmol/l) not
shown; # 3 cases (cortisol 3894-7817 nmol/l) not shown; § 2 cases
(cortisol 4116, 9558 nmol/l) not shown; & 2 cases (cortisol 3858,
3924 nmol/l) not shown.
Table 2 Cortisol values for the different criteria of critical pneumonia
cortisol (nmol/L; median, IQR
a)
Criteria Yes no p-value
Death during antimicrobial treatment (N = 37) 1020 (634-1445) 607 (409-857) < 0.001
ICU-admission (N = 19) 1013 (605-1831) 615 (414-866) 0.002
mechanical ventilation (N = 44) 985 (636-1648) 607 (409-853) < 0.001
catecholamine treatment (N = 5) 1160 (391-1596) 621 (418-866) 0.25
a IQR = interquartile range
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1.02, p = 0.026). After calculating the minor criteria as
suggested by the ATS/IDSA-guideline (with a PaO2 <5 2
mmHg instead of PaO2/FiO2 < 250 and without multilo-
bar infiltrate), the resulting AUC after ROC curve analy-
sis for predicting critical pneumonia was 0.71 with an
optimal cut-off of ≥2 criteria (sensitivity 49%, specificity
88%). Cortisol added significantly to the predictive accu-
racy of this model in binary regression analysis (com-
bined AUC 0.74, p = 0.003).
Discussion
The main study result is that increased serum cortisol
level is associated with the development of critical dis-
ease and increased 30-day-mortality in hospitalised
CAP-patients and adds prognostic information indepen-
dently of the CRB-65 score and the inflammatory bio-
markers WBC and CRP. Serum cortisol level improves
the predictive power of the CRB-65 score and shows
independent prognostic significance within different
CRB-65 strata. Its additional predictive value persisted,
when cortisol was analysed in combination with urea
within the CURB-65 score, PCT or minor criteria
Table 3 Factors predictive for the tested endpoints in multivariate logistic regression analysis, including all variables
given in Table 1
Mortality at 30 days Critical CAP
a
Variable OR (95% CI) p-value OR (95% CI) p-value
Cortisol
b 1.51 (1.13-2.01) 0.005 1.56 (1.20-2.02) 0.001
C-reactive protein
c 0.1 1.45 (1.13-1.87) 0.004
CRB65 1.62 (1.07-2.47) 0.024 3.05 (2.22-4.19) < 0.001
Congestive heart failure 2.20 (1.21-4.03) 0.010 1.96 (1.13-3.39) 0.017
Chronic renal disease 2.05 (1.03-4.04) 0.040 0.64
Malignancy 2.97 (1.50-5.89) 0.002 0.25
Age (years) 1.06 (1.03-1.09) < 0.001 0.87
Male sex 2.13 (1.13-3.99) 0.019 1.73 (1.02-2.94) 0.043
a critical CAP = presence of one of the following: death occurring during antibiotic treatment, mechanical ventilation, catecholamine treatment or ICU admission
b cortisol levels encoded by quartiles in nmol/l: 1. quartile 52-420; 2. quartile 420-621; 3. quartile 621-866; 4. quartile 866-9558
c C-reactive protein levels encoded by quartiles in mg/L: 1. quartile < 1-18.8; 2. quartile 18.8-71.9; 3. quartile 71.9-167; 4. quartile 167-578
Figure 2 ROC-Plot for 30-day mortality, comparing CRB-65
score, cortisol and CRB65-score plus cortisol (p = 0.001 versus
CRB65 score alone).
Figure 3 ROC-Plots for 30-day critical pneumonia, comparing
CRB-65 score, cortisol and CRB65-score plus cortisol (p = 0.002
versus CRB65 score alone).
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[16] to predict ICU-admission.
Our study confirms and expands previous data from
three smaller studies, including a total of 401 patients, sug-
gesting cortisol as biomarker for predicting mortality in
CAP patients [21-23]. The optimal cut-off for mortality
from our data (795 nmol/l) resembles that proposed by
these studies (734 nmol/l in [21], 960 nmol/l in [22] and
820 nmol/l in [23]). The main strength of our study is the
high number of patients included and the rigorous follow
up (only 2/984 missing cases after 30 days), allowing a
more accurate evaluation of mortality and critical pneu-
monia development with a significant number of patients
meeting these endpoints.
Figure 4 Kaplan-Meyer analysis for 30-day mortality according
to cortisol quartiles (2/984 cases censored before day 30).
Figure 5 Kaplan-Meyer analysis for 30-day mortality within
CRB-65 score class 0 (2/984 cases censored before day 30).
Figure 6 Kaplan-Meyer analysis for 30-day mortality within
CRB-65 score class 1 (2/984 cases censored before day 30).
Figure 7 Kaplan-Meyer analysis for 30-day mortality within
CRB-65 score class 2-4 (2/984 cases censored before day 30).
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age, male sex, nursing home residence, chronic comor-
bidities, CRB-65 score and the measured inflammatory
biomarkers to be associated with both endpoints [26,27].
In concordance with previous studies, severe pneumonia
seemed to be less likely to develop in patients with anti-
biotic pre-treatment [28-30]. In multivariate analysis,
only comorbidities, male sex, the CRB-65 score and
serum cortisol predicted both outcomes. The addition of
urea to the CRB-65 score (CURB65-score) in a large sub-
g r o u pa n a l y s i sr e s u l t e di ni m p r o v e m e n to ft h eC R B - 6 5
score, whereas the substitution of age by urea (CURB-
score) did not. If cortisol subsequently was added to
either score, further prognostic improvement of the same
magnitude resulted, suggesting that the prognostic value
of cortisol complements that of urea.
The CAPNETZ study also records the cause of death
as judged by the treating physician. This subjective
statement certainly has a lower value than measured
parameters. But, of the 22 patients who died within 30
days despite having an initial cortisol level below the
cut-off of 795 nmol/l, only three died from pneumonia
as judged by the treating physicians, and two of these
three suffered from concomitant bronchial carcinoma.
Mortality prediction might not be optimal to identify
patients at risk for critical disease manifestations such as
respiratory insufficiency or septic shock. These carry a
high demand on and benefit of intensified management
strategies, which makes their early detection crucial. On
the other hand, CAP frequently occurs in elderly and
multimorbid patients. Here mortality does not always
reflect “dying from pneumonia” but rather “dying with
pneumonia”, and treatment restrictions might bias this
endpoint further. By the inclusion of the predefined com-
posite endpoint of critical pneumonia, our study provides
even more accurate pneumonia-specific risk prediction
than by mortality prediction alone. This dichotomy of
endpoints is reflected by our data: Whereas mortality was
predicted by concomitant malignancy, chronic renal fail-
ure and high age, critical pneumonia was predicted by
higher CRP levels indicating systemic inflammation.
CRB-65-score, congestive heart failure, male sex and
serum cortisol as only biomarker independently pre-
dicted both endpoints, confirming the prognostic rele-
vance of cortisol for CAP-related outcomes.
Rapid and accurate identification of hospitalised CAP
patients at risk of a critical disease course is a yet unmet
need in CAP management. Several scores have been eval-
uated for predicting ICU-admission. The “classical” risk
prediction tools, the CRB-65- and PSI-scores perform
well in identifying patients with a low mortality risk, but
are poor in predicting ICU-admission [14,20]. Recom-
mended tools for this purpose are the modified ATS-rule
[15], consisting of two major criteria (requirement of
mechanical ventilation, presence of septic shock) and
three minor criteria (systolic blood pressure < 90 mmHg,
multilobar involvement, PaO2/FiO2 < 250), and the
newer ATS/IDSA-rule [16], which added 6 more minor
criteria (respiratory rate > 30/min; confusion; blood urea
nitrogen > 20 mg/dl; leukopenia; thrombocytopenia;
hypothermia), thus incorporating all “CRB"-criteria. If
these factors were included in a multivariate analysis
with serum cortisol in our study, only cortisol and the
three CRB-criteria provided independent predictive
power for critical pneumonia, suggesting potential
improvement of this score by complementing or substi-
tuting some of these criteria by cortisol.
To account for the heterogeneous causes for deteriora-
tion in CAP, optimal risk prediction probably should
incorporate clinical criteria plus biomarkers reflecting
inflammatory, cardiovascular and other mechanisms of
disease progression. Accordingly, although inflammatory
markers like CRP [13] and PCT [6,31] are associated with
mortality in CAP, their predictive accuracy does not allow
high risk prediction by themselves. Cardiovascular biomar-
kers like NT-proBNP [11], copeptin, pro-endothelin and
MRpro-ANP [9,32] and others like d-dimer [12] and
proADM [10,33] also predict poor prognosis in CAP.
Cortisol is a biomarker reflecting additional mechan-
isms involved in critical disease development like stress
response and immunomodulatory regulation of inflam-
matory processes [34]. Physiologically, acute stress like
severe illness leads to an activation of the hypothalamic-
pituitary-adrenal axis which protects the organism
against excessive inflammatory responses [35]. In severe
sepsis and septic shock, the increase of serum cortisol
levels parallels the severity of infection and prognosis of
patients [36]. This makes cortisol an attractive biomarker
reflecting acute patterns of critical disease and disease
progression. Recently, three small studies showed that
cortisol correlates to CAP severity and predicts mortality
in CAP-patients. Data from our group additionally
demonstrated, that clinical instability after 72 h, reflect-
ing course and treatment response in CAP, was predicted
by admission cortisol levels [21]. Our present study data
add to that evidence by demonstrating prediction of criti-
cal pneumonia development independently of known
clinical risk factors and inflammatory biomarkers. How-
ever, before cortisol measurement can be recommended
for clinical routine use as biomarker in CAP, a prospec-
tive interventional trial is necessary to prove its accuracy
and cost-effectiveness in comparison to evaluated clinical
scores and competitive biomarkers for predicting patients
benefiting from intensified treatment and monitoring
strategies.
Recently there have been conflicting reports on bene-
fits and risks of steroid treatment in CAP [37,38]. Given
the accumulating evidence of the association of high
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confirmed by the present data, the rationale of steroid
treatment for this condition should be questioned.
Whether the association of high cortisol and poor prog-
nosis reflects adrenal regulation because of more severe
CAP or adrenal dysregulation resulting in a complicated
disease course cannot be concluded from our data and
deserves further study.
Several limitations of our study have to be mentioned:
First, we were not able to correct for concomitant
steroid medication, as this data were not documented.
Systemic steroid medication of ≥ 20 mg prednisolone
equivalent per day for more than 14 days excludes parti-
cipation in CAPNETZ. In order to control for potential
effects of steroid co-medication, which probably affect
patients with chronic respiratory disease in particular,
analysis after exclusion of all patients with chronic
respiratory disease was performed and no relevant
change of the diagnostic properties of cortisol could be
detected.
Second, as blood samples were taken at time of first
contact, controlling for the time point of blood sampling
could not be done. Cortisol exhibits diurnal concentra-
tion changes; however, during infectious diseases the
circadian pattern is often lost [39].
Third, we did not test for adrenal insufficiency based
on the response to injection of synthetic adrenocortico-
tropin. However previous data show a very low rate of
adrenal insufficiency in patients with CAP in the
absence of septic shock [21], and the association of mor-
tality with high cortisol levels seems to contradict any
major prognostic influence.
Thus, deviation of our study results by concomitant
steroid medication, adrenal insufficiency or different
blood sampling time points cannot be ruled out. These
limitations also might account for the slightly lower pre-
dictive performance of cortisol shown in our study
when compared to some of the previous data (AUC for
mortality in our data 0.70; 0.76 in [22], 0.65 in [23], 0.83
in [21]). Standardised blood collection at the same day-
time in all patients and rigorous exclusion of oral ster-
oid co-medication would most probably have resulted in
a higher accuracy but does not reflect daily clinical prac-
tice. Therefore, this lack of standardisation might also
be interpreted in favour of the robustness of the associa-
tion between serum cortisol and CAP outcomes.
Finally, a comparison with other non-inflammatory
biomarkers of CAP prognosis or new risk scores
recently evaluated to predict ICU admission in CAP like
the SMART-COP score [40] is not available from our
data; and comparison with urea, PCT and the ATS/
IDSA-minor criteria have been calculated in post-hoc
analyses with data not complete for all patients.
Conclusions
In conclusion, cortisol predicts mortality and critical dis-
ease in hospitalised CAP-patients independently of clini-
cal factors and inflammatory biomarkers. Recognizing
the need for early identification of patients requiring
intensive management strategies and the complex
mechanisms involved in critical disease development in
CAP, cortisol represents a promising biomarker for high
risk prediction. In order to implement its use into clini-
cal practice, the optimal combination of clinical factors
and biomarkers for high risk prediction in hospitalised
CAP should be evaluated in a large prospective trial.
Ideally, this would include an interventional design,
assessing the guidance of more intensive monitoring
and management strategies based on a combined risk
stratification tool consisting of clinical factors and bio-
markers like cortisol.
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